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Abstract
 
A proliferation-inducing ligand (APRIL) is a ligand of the tumor necrosis factor (TNF) family
that stimulates tumor cell growth in vitro and in vivo. Expression of APRIL is highly upregu-
lated in many tumors including colon and prostate carcinomas. Here we identify B cell matura-
tion antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin
ligand (CAML) interactor (TACI), two predicted members of the TNF receptor family, as re-
ceptors for APRIL. APRIL binds BCMA with higher affinity than TACI. A soluble form of
BCMA, which inhibits the proliferative activity of APRIL in vitro, decreases tumor cell prolif-
eration in nude mice. Growth of HT29 colon carcinoma cells is blocked when mice are treated
once per week with the soluble receptor. These results suggest an important role for APRIL in
tumorigenesis and point towards a novel anticancer strategy.
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Introduction
 
TNF-related ligands can induce pleiotropic biological re-
sponses. Many of the ligands trigger costimulatory growth
signals in primary cells, lead to the activation of nuclear fac-
 
tor (NF)-
 
k
 
B, or even induce cell death. A proliferation-
 
inducing ligand (APRIL) has the unique capacity to stimulate
the growth of transformed tumor cell lines (1). The devel-
opment of cancer is viewed as a multistep process involving
mutation and progressive selection for cells with increasing
capacity for proliferation, survival, and invasion, even un-
der conditions where the growth factor supply is limited.
APRIL allows tumor cells to proliferate at a reasonable rate
even in low serum (1). Moreover, APRIL is abundantly
expressed in many tumor cells and tumor tissues, in partic-
ular gastrointestinal tumors, including rectum, duodenum,
colon, stomach, and esophagus (1, 2), suggesting that
APRIL may function as an autocrine growth factor during
tumorigenesis. APRIL is a close sequence homologue of B
cell activation factor of the TNF family (BAFF, also known
as BLyS/zTNF4/TALL-1) (3, 4). BAFF, a costimulator of
B lymphocyte survival and proliferation, has two known
receptors, B cell maturation antigen (BCMA) and trans-
membrane activator and calcium modulator and cyclophi-
lin ligand (CAML) interactor (TACI) (4–7). In this study,
we demonstrate that TACI and BCMA also bind to
APRIL and that inhibition of APRIL with a soluble form
of BCMA interferes with tumor growth in vivo, suggesting
an important role of APRIL in carcinogenesis.
 
Materials and Methods
 
Recombinant Proteins, Transient Transfections, and Stable Cell
Lines.
 
Receptors–Fc fusion proteins and Flag-tagged ligands
(hAPRIL amino acids [aa] 110–250, mAPRIL aa 88–232) were
produced in 293T cells essentially as described (1, 8). For FACS
 
®
 
stainings, a soluble APRIL was used in which the oligomerization
domain of murine adipocyte complement-related protein 30 kD
(aa 18–111) was inserted 3
 
9
 
 of the Flag sequence and 5
 
9 
 
of the
APRIL sequence. This chimeric protein has the same receptor
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binding properties as Flag–APRIL and improved background
staining by FACS
 
®
 
. Flag-tagged hBAFF and 293–BAFF cells have
been previously described (3). A cDNA encoding the fusion pro-
tein hBAFF (aa 1–132)–hAPRIL (aa 110–250) was cloned in
PCR-3 expression vector and stably transfected into 293 cells fol-
lowing established protocols (8).
Myc-tagged mAPRIL (aa 98–232) cloned into a pPIC9 (Invit-
rogen) derived vector was expressed in 
 
Pichia pastoris 
 
strain GS115
grown in BMMY medium (Invitrogen). Pichia supernatant was
dialyzed overnight against 10 mM Tris, pH 6.8, and then loaded
onto a Sepharose–SP column. The column was washed exten-
sively with 10 mM Tris/HCl, pH 6.8, and eluted with 250 mM
NaCl in PBS. A second purification step was performed using a
gel filtration column (S300; Amersham Pharmacia Biotech). The
purified protein was analyzed by Western blot using the mono-
clonal 9E10 (anti-Myc) antibody and NH
 
2
 
-terminal sequence de-
termination.
 
Immunoprecipitations, Receptor Binding ELISA, and Flow Cytome-
try.
 
Receptors–Fc (
 
z
 
500 ng) mixed with Flag ligands (200 ng)
in 1 ml of PBS were incubated for 2 h at 4
 
8
 
C on a wheel with 2.5
 
m
 
l of protein A–Sepharose (Amersham Pharmacia Biotech).
Beads were harvested, loaded in empty mini columns, washed
three times with 100 volumes of PBS, eluted with 15 
 
m
 
l of 0.1 M
citrate-NaOH, pH 2.7, neutralized, and analyzed by Western
blotting with anti-Flag M2 antibody. Membranes were subse-
quently reprobed with goat anti–human IgG antibodies.
Receptor binding ELISA was performed essentially as de-
scribed (8). In brief, receptors–Fcs were coated to ELISA plates in
carbonate buffer. After blocking, serial dilutions of Flag ligands
were added, and ligand binding was revealed with anti-Flag M2
antibody.
Staining using the rat IgG2a anti-hBAFF antibody Buffy-1
(formerly 43.9) was performed as described (3). Stable cell lines
expressing surface BAFF or surface APRIL were stained with 200
ng hBCMA–Fc, followed by goat anti–human–PE antibodies (1/
100) (Southern Biotechnology Associates, Inc.). NIH3T3 cells
were stained with Flag–BAFF (100 ng per staining), Flag–APRIL
(100 ng per staining), or with Flag–APRIL that had been previ-
ously depleted using protein A beads loaded with BCMA–Fc or
TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2)–
Fc (25 
 
m
 
g). A 500-fold depletion was achieved with BCMA–Fc,
as assessed by ELISA on BCMA–Fc. Bound ligands were revealed
with biotinylated anti-Flag M2 antibody and PE-coupled strepta-
vidin as previously described (3, 4).
 
Northern Blots.
 
Total RNA was obtained from 
 
z
 
10
 
7
 
 cells us-
ing the RNeasy purification system (QIAGEN). 20 
 
m
 
g of RNA
per sample was run on a 1.2% agarose gel containing formalde-
hyde and transferred to a nylon membrane. The Northern blots
were hybridized using random primed radioactive probes in Ex-
pressHyb buffer (CLONTECH Laboratories, Inc.) for 
 
z
 
3 h and
then washed at room temperature for 40 min with several
changes of 2
 
3
 
 SSC/0.1% SDS followed by 0.1
 
3
 
 SSC/0.05%
SDS for 40 min at 50
 
8
 
C. The blots were probed with human or
mouse BCMA, TACI, or actin.
 
APRIL-transfected Cell Lines.
 
The tetracycline-inducible
mAPRIL–expressing cell lines were constructed using the Tet-
On™ expression system (CLONTECH Laboratories, Inc.). In brief,
the soluble extracellular domain of murine APRIL was PCR
amplified using primers 5
 
9
 
-TGTGAATTCCGGCCCCACCAT-
GGATTACAAAGACGATGACGATAAAGGGGGCTCAGT-
CAGTCAGAGAGCC-3
 
9
 
 and 5
 
9
 
-TGTCTAGATCATAGTTT-
CACAAACCCCAGG-3
 
9
 
, which allowed directional cloning
into the pTRE vector. This APRIL expression vector was stably
transfected along with a hygromycin selection plasmid into a cell
line that had already been stably transfected, under neomycin se-
lection, with the pTet-on regulatory plasmid. Cell lines derived
from this dual selection process were then selected on the basis of
induction of APRIL expression in the presence of the tetracycline
analogue doxycycline (2 
 
m
 
g/ml; Sigma-Aldrich). Cell extracts of
stable clones were analyzed by Western blotting using anti-Flag
M2 mAb (Sigma-Aldrich).
For cellular proliferation analyses, the Tet-inducible APRIL
expression lines were maintained in 0.5% serum overnight to in-
duce quiescence. Cells were then plated in 96-well plates at a
concentration of 10
 
5
 
 cells/ml in RPMI/1% serum and were left
untreated, received 2 
 
m
 
g/ml doxycycline, or received doxycyc-
line and 20 
 
m
 
g/ml BCMA–Fc fusion protein. Cells were left
overnight and then pulsed for 8 h with 0.5 
 
m
 
Ci/well [
 
3
 
H]thymi-
dine (Amersham Pharmacia Biotech).
 
Tumor Models.
 
Tumor growth was investigated using 6–8-
wk-old female nude (Nu/Nu) mice (Harlan Laboratories). Tu-
mor cell lines HT29 and A549 were obtained from American
Type Culture Collection and cultured following the supplier’s
instructions. Cells were trypsinized, washed twice, and resus-
pended in pyrogen-free PBS at a concentration of 10
 
7 
 
cells/ml.
Mice were anesthetized using a ketamine/xylazine solution, and
100 
 
m
 
l of cells was carefully implanted in the flank subcutane-
ously. Mice were injected with purified proteins intraperitoneally
just before tumor implantations and weekly thereafter. Dosing
was 200 
 
m
 
g BCMA–Fc or control hIgG in 100 
 
m
 
l PBS intraperi-
toneally. Tumor diameter was measured at various times after im-
plantation using a caliper. Tumor volume was calculated using
the formula v 
 
5
 
 4/3
 
p
 
R
 
3
 
. Statistical significance was determined
using mean equivalence tests.
 
Results and Discussion
 
As APRIL is a member of the TNF ligand family, it was
likely that it interacted with one of the currently known 25
members of the TNF receptor family, some of which are
still orphan (9). When supernatants from 293T cells ex-
pressing recombinant soluble Flag-tagged APRIL (aa 110–
250, corresponding to the TNF homology region) were
incubated with various soluble TNF receptor–Ig-Fc fusion
proteins (receptor–Fc), two of them, BCMA–Fc and
TACI–Fc, were found to immunoprecipitate APRIL. In
contrast, no specific interaction with other receptors, in-
cluding herpes virus entry mediator (HVEM) and Fas,
which have been recently proposed to interact with
APRIL (2), was observed (Fig. 1 A). BCMA and TACI are
atypical TNF receptor family members (5, 6). Both are de-
void of a signal sequence and contain one (BCMA) or two
(TACI) sets of A and C cysteine-rich modules instead of
multiple A and B modules found in most other TNF re-
ceptor members (10). Recently, BCMA and TACI have
been identified as receptors for BAFF/BLyS/zTNF4/
TALL-1 (4). BAFF, which promotes B cell survival and
proliferation, is the closest sequence homologue of APRIL
(3). Thus, both BCMA and TACI can act as receptors for
the same two ligands, APRIL and BAFF.
BCMA–Fc and TACI–Fc did not immunoprecipitate
any of the 14 other TNF ligand family members tested,
confirming that the interactions with APRIL and BAFF 
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were specific (data not shown). Moreover, when human or
murine BCMA–Fc was coated to plastic, specific binding
of both human and murine APRIL was found in each case
(Fig. 1 B), indicating that there is ligand–receptor cross-
species reactivity. Binding of human and murine APRIL to
human TACI–Fc was weaker in this format (Fig. 1 B). In
contrast, human BAFF bound TACI–Fc with similar affin-
ity (Fig. 1 B), in agreement with recent data (4).
Binding of BCMA–Fc was not restricted to soluble
ligands but was also observed with membrane-bound
Figure 1. APRIL is a ligand for the TNF receptors BCMA and TACI. (A) Var-
ious receptor–Fc fusion proteins of the TNF receptor family (0.5 mg) were mixed
with Flag-tagged soluble hAPRIL (0.2 mg), immunoprecipitated with protein-A,
and detected by Western blotting with antibodies to human Ig (top panel). Coim-
munoprecipitating APRIL was detected with anti-Flag antibodies (bottom panel).
(B) Binding of Flag-APRIL and Flag-BAFF to plastic-coated BCMA–Fc, TACI–
Fc, or TRAILR2–Fc (control) was assessed by ELISA. Flag–ligands were added at
the indicated concentrations, and their binding was revealed using anti-Flag M2
antibody. (C) Binding of BCMA–Fc to 293 cells (ctrl) and to 293 cells stably trans-
fected with full-length hBAFF (BAFF) or with a fusion protein in which the TNF
homology domain of BAFF had been replaced by that of APRIL. The same cells
were also stained with anti-hBAFF mAb (Buffy-1) to determine the absolute
amount of surface expressed ligands (right panel). The epitope recognized by
Buffy-1, which is close to the membrane, is retained in the APRIL fusion protein,
as shown in the scheme. (D) Mixtures of Flag-tagged BAFF (10 mg) and Myc-
tagged APRIL (10, 1, 0.1, or 0.01 mg) were immunoprecipitated with substoechi-
ometric amounts of BCMA–Fc (0.2 mg) and analyzed by Western blotting.
Ligands were detected simultaneously with anti-Flag and anti-Myc antibodies (top
panel), and BCMA–Fc with antibodies to hIg (bottom panel). 
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APRIL and BAFF. 293HEK cells were stably transfected
with a BAFF or with a BAFF (stalk region)–APRIL (TNF
homology region) hybrid ligand (Fig. 1 C). Using the anti-
BAFF stalk antibody (Buffy-1), similar surface expression
levels of BAFF and of the APRIL hybrid construct were
demonstrated in stably transfected cell populations. We
found that BCMA–Fc bound more strongly to APRIL
than to BAFF (Fig. 1 C). Moreover, when equal concen-
trations of Myc–APRIL and Flag–BAFF were incubated
with BCMA–Fc, only APRIL was detected in BCMA–Fc
Figure 2. In vitro prolifera-
tion induced by APRIL expres-
sion is blocked by soluble hB-
CMA–Fc fusion protein. (A)
Western blot analysis of APRIL
expression in the presence or ab-
sence of doxycycline (dox), a
tetracycline analogue that in-
duces expression. Two indepen-
dently derived lines are shown.
The major APRIL bands at 17
and 22 kD are indicated. (B)
[3H]thymidine incorporation in
the presence or absence of doxy-
cycline with or without 20 mg/
ml of hBCMA–Fc added. Values
shown are 3H incorporation
(inc.) expressed as percent of
control. Two different experi-
ments are shown. P < 0.02; n =
3 wells per data point.
Figure 3. Expression of APRIL
receptors. Northern blot showing
expression of TACI and BCMA
mRNA in various human (A) and
murine (B) cell lines. Probing with
b-actin gave comparable signals for
all cell lines (data not shown). B cell
lines: J558, BW5147, A20, U266,
RPMI8226, Ramos, Namalwa,
NC-37, IM-9, SKW6.4, Raji,
Daudi, BJAB; monocytic line:
U937; T cell line: Jurkat; adenocar-
cinoma cell lines: HT29, SW480;
lung carcinoma cell line: A549; mel-
anoma cell line: ME260; fibroblast-
derived cell line: NIH-3T3. (C)
Flow cytometric analysis of NIH-
3T3, HT-29, A459, and Raji cells
stained with Flag–BAFF (BAFF),
Flag–APRIL (APRIL), Flag–APRIL
depleted with BCMA–Fc
(1BCMA) or, as control, Flag–
APRIL depleted with TRAILR2–
Fc (1TRAILR2). Bound ligands
were detected with anti-Flag mAb. 
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immunoprecipitates (Fig. 1 D). A great excess of BAFF
over APRIL was required to inhibit APRIL binding.
These data suggest that although BCMA and TACI are
both receptors for APRIL and BAFF, some specificity of
interaction may be imposed by the apparent preference of
BCMA for APRIL and of TACI for BAFF.
We have previously shown that NIH-3T3 cells stably
transfected with full-length human APRIL proliferate faster
than mock-transfected cells in vitro and in vivo (1). As
membrane-bound APRIL is predicted to be efficiently
processed in the extracellular stalk region by a furin to re-
lease soluble (s)APRIL (3), we next investigated whether
increased proliferation rates were also discernible in cell
lines that directly expressed the soluble form. NIH-3T3
clones that expressed soluble murine APRIL under a tetra-
cycline-inducible promotor were generated. sAPRIL ex-
pression could be induced by treatment with the tetracy-
cline analogue doxycycline for 16 h (Fig. 2 A). In Western
blots, two forms of sAPRIL migrating at 17 and 22 kD
were detected that corresponded to the expected sizes of
the nonglycosylated and 
 
N
 
-glycosylated proteins, respec-
tively. We maintained the tet-inducible APRIL expression
clones in low serum to induce quiescence, and the cells
were then either left untreated or incubated with doxycy-
cline overnight. When proliferation was assayed using a
[
 
3
 
H]thymidine pulse, induced sAPRIL cell lines showed a
30–40% increase in proliferation rate (Fig. 2 B). This in-
crease in growth rate is comparable to that observed with
NIH-3T3 clones stably expressing the membrane-bound
APRIL (1). In the presence of BCMA–Fc, the increased
proliferation observed in sAPRIL-expressing cells was re-
versed (Fig. 2 B), indicating that the growth advantage was
indeed APRIL mediated.
As BCMA and TACI mRNA expression was reported
exclusively in B cells or activated T cells (5, 6), the prolifer-
ative effect of APRIL on the fibroblastic NIH-3T3 cells
was difficult to explain. We therefore measured mRNA
levels of the two APRIL receptors in a panel of murine and
human cell lines and could confirm the previously reported
cell type distribution (Fig. 3, A and B). In no case were
BCMA or TACI mRNA detected in nonlymphoid cells
such as the human adenocarcinoma cell line HT-29, the
lung carcinoma cell line A549, or the murine fibroblastic
NIH-3T3 cell line, even after prolonged Northern blot ex-
posure. As expected from the Northern blot data, we were
unable to stain these cells with BAFF, further supporting
their lack of BCMA or TACI expression (Fig. 3 C). In
contrast, a strong staining of these cells was observed with
Flag–APRIL, which could be partially reduced by prior
depletion of Flag–APRIL with BCMA–Fc, but not with
the control TRAILR2–Fc (Fig. 3 C). The control Raji
cells, which express message for both TACI and BCMA,
were positive for both BAFF and APRIL staining as ex-
pected. Taken together, these results suggest that NIH-
3T3, HT-29, A549, and other fibroblastic and epithelial
cell lines (data not shown) express a third yet uncharacter-
ized APRIL receptor that does not cross-react with BAFF
(Fig. 3).
The availability of a soluble high-affinity APRIL recep-
tor (BCMA–Fc) capable of inhibiting APRIL-proliferative
effects in vitro allowed us to investigate the role of APRIL
in tumorigenesis. When the epithelial tumor cell line
HT29 was grown as subcutaneous tumors in nude mice,
small palpable tumors were observed 2 wk after injection,
and the average tumor volume exceeded 0.5 cm
 
3
 
 after 6
wk. Treatment with human BCMA–Fc (200 
 
m
 
g per mouse
every week, the first time immediately before tumor cell
injection) almost completely blocked tumor formation, and
even 6 wk after injection, tumors were barely detectable.
The human lung carcinoma cell line A549 was also grown
as a subcutaneous tumor and subjected to the same treat-
ment course. 7 wk after tumor implantation, the average
tumor size was 0.15 cm
 
3
 
. Injection of BCMA–Fc retarded
tumor growth, resulting in a significant reduction of tumor
size to 
 
,
 
0.10 cm
 
3
 
 (Fig. 4 B). This difference was still very
significant 10 wk after tumor implantation, indicating that
BCMA–Fc can modulate tumor growth over a long period
of time (Fig. 4 B). Results similar to the A549 case were
obtained with SW480 cells and NIH-3T3 cells (data not
shown).
Several mechanisms could contribute to the retardation
of tumor growth in BCMA–Fc-treated animals. Most tu-
mor cell lines investigated in this report express endoge-
nous APRIL (reference 1 and additional Northern blot data
Figure 4. Growth of human adenocarcinoma and lung carcinoma cell
lines in nude (Nu/Nu) mice. (A) Growth rate of HT29 tumors implanted
subcutaneously. Mice were left untreated or were treated with purified
BCMA–Fc (200 mg) or control hIgG (200 mg) on day of inoculation and
weekly thereafter. The scattergram showing tumor volume in pooled
control mice and BCMA–Fc-treated mice 6 wk after HT29 tumor im-
plantation is shown in the right panel. (B) Scattergrams showing tumor
volume in pooled control mice and BCMA–Fc-treated mice 7 wk (left
panel) and 10 wk (right panel) after subcutaneous implantation of A549
lung carcinoma cells. *P = 0.06; **P = 0.01; ***P < 0.005. 
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not shown), and, because increased levels of APRIL en-
hance proliferation in vitro, it is possible that BCMA–Fc
interferes with autocrine APRIL-mediated growth signals.
TACI and BCMA signaling leads to increased activation of
the transcription factor NF-
 
k
 
B (and nuclear factor of acti-
vated T cells and activator protein [AP]-1 for TACI
through CAML) (5), and constitutive NF-
 
k
 
B and AP-1 ac-
tivation is frequently found in highly tumorigenic cells
(11). Therefore, a high local concentration of furin-pro-
cessed soluble APRIL (3), perhaps together with increased
expression of APRIL receptors, will potentially result in
conditions that favor neoplastic growth. In this context, it
is noteworthy that BCMA was originally identified as a
gene fused to the IL-2 locus in a chromosomal transloca-
tion from a T lymphoma (12). However, the growth stim-
ulatory effects of APRIL on NIH-3T3 cells are unlikely to
be due to the stimulation of the BCMA or TACI signaling
pathways, as these cells do not express detectable amounts
of these receptors. As strong APRIL binding to NIH-3T3
and other cells is observed, it is reasonable to assume that fi-
broblasts express an additional APRIL receptor that, in
contrast to BCMA and TACI, does not appear to cross-
react with BAFF. We are currently attempting to charac-
terize this putative receptor.
High levels of APRIL mRNA expression have been de-
scribed in carcinomas (1, 2), a tumor class in which muta-
tions in the tumor suppressor p53 gene are frequently
found (13). As APRIL is localized on chromosome
17p13.1, 130–150 kb telomeric to p53 (14), it is conceiv-
able that an increased local transcriptional activity may con-
tribute to augment APRIL expression. We cannot rule out,
however, that the action of BCMA–Fc is indirect. BCMA–
Fc may interfere with APRIL produced by host cells,
which may stimulate tumor growth in a paracrine manner.
Moreover, as administration of BCMA–Fc has been dem-
onstrated to partially deplete B cells in mice (4, 7), the ef-
fect of BCMA–Fc on B cells has to be considered. We feel,
however, that this latter possibility is unlikely given that
nude mice lack T cells necessary for B cell help.
APRIL’s growth-stimulatory capacity on transformed
cells together with the observation that the growth of
tumor cell lines is suppressed upon interference with
APRIL’s activity suggests an important role for APRIL in
tumorigenesis. Therefore, a potential role for APRIL in
supporting the growth of B cell tumors that express high
levels of BCMA should also be considered. Indeed, stimu-
lation of BCMA and/or TACI leads to increased Bcl-2 ex-
pression in primary B cells (15), and the Raji Burkitt lym-
phoma cell line has enhanced growth in the presence of
APRIL (1). Interestingly, Burkitt lymphoma cells require
signals from monocytes for optimal survival and prolifera-
tion (16). As APRIL is expressed in monocytes (our un-
published observations), it is possible that APRIL may
provide this stimulus. Such a signal may be a critical com-
ponent in tumorigenesis in a variety of settings. For exam-
ple, chronic inflammation in inflammatory bowel disease or
after 
 
Helicobacter pylori
 
 infection in humans has been impli-
cated in the pathogenesis of cancers of the gastrointestinal
tract, suggesting that tumor cells receive stimulatory signals
from inflammatory cells (17).
Cancer is a major public health problem despite impres-
sive advances in the understanding of molecular mecha-
nisms underlying carcinogenesis and in the development of
novel anticancer therapies. The recent success of antibodies
to epidermal growth factor receptor2 (HER2) in the treat-
ment of breast cancer tumors (18) demonstrates that anti-
bodies or antibody-like molecules can effectively be used
to treat cancer patients, complementing classical drugs.
BCMA–Fc or other inhibitors interfering with APRIL ac-
tivity may therefore constitute exciting new tools in cancer
therapy.
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